Phase 3 MOTION Trial Efficacy and Safety

The faculty review the phase 3 MOTION trial of vimseltinib in TGCT, describing the results as robust. CSF1 inhibitors are described as shrinking tumors and addressing the inflammatory component of the disease, with a waterfall plot showing benefit in nearly every patient. About 40% of patients had a response by Response Evaluation Criteria in Solid Tumors (RECIST) at 6 months. Side effects they list include facial swelling with a feeling of heaviness, skin irritation, and gastrointestinal upset. A key point is that MOTION did not show the hepatotoxicity seen with earlier CSF1 inhibitors, a leading patient concern. The faculty also value patient-reported outcomes as an objective assessment of a subjective experience.